ERBB2 and breast cancer: While luminal (A and B) BC is characterized by the presence of hormone receptors estrogen and progesterone positive (ER+ and/or PR+) biomarkers with good prognosis, HER2 enriched are hormone receptor negative and HER2 positive BC accompanied by a relatively worse prognosis.